|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.26 - 13:06
|
Xeris Biopharma Reports Second Quarter 2026 Financial Results (Business Wire)
|
|
|
Total revenue increased to over $92 million
Net product revenue increased 34% year-over-year to over $91 million
Recorlev net revenue increased 81% year-over-year to approximately $57 million
Tightens full-year 2026 total revenue guidance to $385 million to $390 million
Conference call and webcast today at 8:30 a.m. ETCHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026.
"The second quarter was another strong period for Xeris, with net product revenue growing 34% year-over-year, driven by Recorlev's exceptional commercial momentum,” said John Shannon, Chairman and Chief Executive Officer of Xeris. "The strategic investments we made for Recorlev earlier this year are gaining traction, and we expect their contribution to become increasin...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
